Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers.
Age of Onset
Antineoplastic Agents
/ history
Child
Drug Discovery
/ history
Drug Resistance, Neoplasm
/ drug effects
Drug Screening Assays, Antitumor
/ history
Gene Expression Regulation, Neoplastic
/ drug effects
History, 20th Century
History, 21st Century
Humans
N-Myc Proto-Oncogene Protein
/ antagonists & inhibitors
Neoplasms
/ drug therapy
Therapies, Investigational
/ history
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
12
10
2020
revised:
28
12
2020
accepted:
22
01
2021
pubmed:
30
1
2021
medline:
12
8
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
Effective treatment of pediatric solid tumors has been hampered by the predominance of currently "undruggable" driver transcription factors. Improving outcomes while decreasing the toxicity of treatment necessitates the development of novel agents that can directly inhibit or degrade these elusive targets. MYCN in pediatric neural-derived tumors, including neuroblastoma and medulloblastoma, is a paradigmatic example of this problem. Attempts to directly and specifically target MYCN have failed due to its similarity to MYC, the unstructured nature of MYC family proteins in their monomeric form, the lack of an understanding of MYCN-interacting proteins and ability to test their relevance
Identifiants
pubmed: 33509943
pii: 0008-5472.CAN-20-3108
doi: 10.1158/0008-5472.CAN-20-3108
pmc: PMC8392692
mid: NIHMS1734303
doi:
Substances chimiques
Antineoplastic Agents
0
MYCN protein, human
0
N-Myc Proto-Oncogene Protein
0
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1627-1632Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM118090
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA128583
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Clin Cancer Res. 2019 Jun 1;25(11):3229-3238
pubmed: 30777875
Cell Stem Cell. 2019 Sep 5;25(3):433-446.e7
pubmed: 31204176
iScience. 2020 Oct 06;23(10):101641
pubmed: 33103079
Nature. 2015 Sep 24;525(7570):538-42
pubmed: 26367796
Structure. 2000 Mar 15;8(3):329-38
pubmed: 10745017
Cancer Cell. 2009 Jan 6;15(1):67-78
pubmed: 19111882
Clin Cancer Res. 2016 Nov 15;22(22):5564-5573
pubmed: 27440268
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24269-24273
pubmed: 32913054
J Biomol Screen. 2013 Mar;18(3):258-68
pubmed: 23042076
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Oncoimmunology. 2017 Apr 28;6(6):e1320626
pubmed: 28680756
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731
pubmed: 27837025
Essays Biochem. 2017 Nov 8;61(5):431-437
pubmed: 29118091
Clin Cancer Res. 2018 Nov 15;24(22):5673-5684
pubmed: 29784674
Cancer Discov. 2013 Mar;3(3):308-23
pubmed: 23430699
J Am Chem Soc. 2009 Jun 3;131(21):7390-401
pubmed: 19432426
Cancer Cell. 2017 Feb 13;31(2):270-285
pubmed: 28089889
Cancer Discov. 2018 Feb;8(2):150-163
pubmed: 29358508
Sci Rep. 2016 Aug 03;6:30955
pubmed: 27485036
Cancer Discov. 2016 May;6(5):492-500
pubmed: 26976114
Biochem Soc Trans. 2017 Jun 15;45(3):709-717
pubmed: 28620032
Nature. 2020 Jan;577(7790):426-431
pubmed: 31775157
Nature. 1986 Jan 2-8;319(6048):73-7
pubmed: 3510398
Nat Methods. 2020 Jan;17(1):79-85
pubmed: 31768063
J Clin Oncol. 2018 Oct 20;36(30):3007-3014
pubmed: 29733771
Curr Opin Struct Biol. 2019 Feb;54:10-18
pubmed: 30316104
Mol Cell. 2018 Dec 6;72(5):836-848.e7
pubmed: 30415952
Nature. 2019 Feb;566(7743):224-229
pubmed: 30728502
Cancer Cell. 2019 Nov 11;36(5):483-497.e15
pubmed: 31679823
Cell. 2019 Sep 19;179(1):193-204.e14
pubmed: 31495574
Genes Dev. 2010 May 15;24(10):1059-72
pubmed: 20478998
Cell. 2003 Jan 24;112(2):193-205
pubmed: 12553908
Nature. 2017 Sep 7;549(7670):96-100
pubmed: 28854174
J Mol Biol. 2005 Aug 5;351(1):182-94
pubmed: 15992821
Cell Rep. 2016 Aug 2;16(5):1273-1286
pubmed: 27452461
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9
pubmed: 31693904
Mol Cell Biol. 1991 Feb;11(2):954-62
pubmed: 1990293
Pediatr Blood Cancer. 2020 Jun;67(6):e28267
pubmed: 32307821
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Nat Rev Cancer. 2019 Nov;19(11):611-624
pubmed: 31511663
Cell Rep. 2017 Dec 19;21(12):3483-3497
pubmed: 29262328
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Sci Rep. 2016 Sep 27;6:33926
pubmed: 27671553
Cell. 1986 Dec 5;47(5):667-74
pubmed: 3096575
EMBO J. 1997 Jun 2;16(11):2985-95
pubmed: 9214616
Cancer Cell. 2014 Sep 8;26(3):414-427
pubmed: 25175806
Nature. 2018 Aug;560(7720):607-612
pubmed: 30135578
Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34
pubmed: 20108338
Mol Cell. 2015 May 7;58(3):440-52
pubmed: 25818646
Nucleic Acids Res. 2012 Jul;40(13):6353-66
pubmed: 22457068
Nat Chem Biol. 2020 Nov;16(11):1179-1188
pubmed: 32989298
Biomaterials. 2018 Sep;178:193-203
pubmed: 29936153
Curr Opin Chem Biol. 2010 Aug;14(4):481-8
pubmed: 20598937
Oncotarget. 2016 Nov 22;7(47):77378-77388
pubmed: 27764802
Cancer Cell. 2018 Dec 10;34(6):922-938.e7
pubmed: 30537514
Lancet Haematol. 2016 Apr;3(4):e186-95
pubmed: 27063977
Clin Cancer Res. 2012 Nov 1;18(21):6058-64
pubmed: 22988055
Cell. 2020 Apr 2;181(1):102-114
pubmed: 31955850
Nat Rev Drug Discov. 2016 Sep;15(9):605-619
pubmed: 27417849
Lancet Haematol. 2016 Apr;3(4):e196-204
pubmed: 27063978
Acta Neuropathol. 2020 Aug;140(2):209-225
pubmed: 32519082
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
Nat Struct Mol Biol. 2019 Nov;26(11):1035-1043
pubmed: 31686052
Nat Rev Cancer. 2017 Aug;17(8):502-508
pubmed: 28643779
Sci Rep. 2019 Jan 23;9(1):321
pubmed: 30674905
Annu Rev Biochem. 2018 Jun 20;87:479-502
pubmed: 29328784
Cancer Cell. 2016 Jan 11;29(1):5-16
pubmed: 26766587